Thrombolytic therapy of ischemic stroke
Reperfusion therapy is one of the main treatment strategies of ischemic stroke. The first studies of the efficacy of thrombolytic medications started form the use of streptokinase and fibrinolysin in patients with ischemic stroke in late 50 - early 60 of the XX century in the United States, Soviet Union, and Western Europe. After the development of recombinant tissue plasminogen activator, thrombolysis became one of the main methods of reperfusion in patients with acute ischemic stroke, acute myocardial infarction, or other acute vascular thrombotic events. Later, modified variants of tissue plasminogen activator with prolonged clearance time, high fibrin-selectivity, and bolus delivery were introduced. Another group of thrombolytic agents includes derivatives of flora and fauna - external plasminogen activators, of which streptokinase, staphylokinase, and desmoteplase are most common drugs. These medications are not a structural part of the human organism, and overcoming of immunogenicity while preserving fibrinolytic activity and fibrin specificity is one of the main tasks in applying them in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova - 118(2018), 12. Vyp. 2 vom: 30., Seite 4-14 |
| Sprache: |
Russisch |
|---|
| Weiterer Titel: |
Tromboliticheskaia terapiia ishemicheskogo insul'ta |
|---|
| Beteiligte Personen: |
Gusev, E I [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.05.2019 Date Revised 20.05.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.17116/jnevro20181181224 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294543201 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294543201 | ||
| 003 | DE-627 | ||
| 005 | 20231225081718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17116/jnevro20181181224 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0981.xml |
| 035 | |a (DE-627)NLM294543201 | ||
| 035 | |a (NLM)30830111 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Gusev, E I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thrombolytic therapy of ischemic stroke |
| 246 | 3 | 3 | |a Tromboliticheskaia terapiia ishemicheskogo insul'ta |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2019 | ||
| 500 | |a Date Revised 20.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Reperfusion therapy is one of the main treatment strategies of ischemic stroke. The first studies of the efficacy of thrombolytic medications started form the use of streptokinase and fibrinolysin in patients with ischemic stroke in late 50 - early 60 of the XX century in the United States, Soviet Union, and Western Europe. After the development of recombinant tissue plasminogen activator, thrombolysis became one of the main methods of reperfusion in patients with acute ischemic stroke, acute myocardial infarction, or other acute vascular thrombotic events. Later, modified variants of tissue plasminogen activator with prolonged clearance time, high fibrin-selectivity, and bolus delivery were introduced. Another group of thrombolytic agents includes derivatives of flora and fauna - external plasminogen activators, of which streptokinase, staphylokinase, and desmoteplase are most common drugs. These medications are not a structural part of the human organism, and overcoming of immunogenicity while preserving fibrinolytic activity and fibrin specificity is one of the main tasks in applying them in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a alteplase | |
| 650 | 4 | |a desmoteplase | |
| 650 | 4 | |a ischemic stroke | |
| 650 | 4 | |a lanoteplase | |
| 650 | 4 | |a monteplase | |
| 650 | 4 | |a pamiteplase | |
| 650 | 4 | |a plasmin | |
| 650 | 4 | |a plasminogen | |
| 650 | 4 | |a plasminogen activators | |
| 650 | 4 | |a reteplase | |
| 650 | 4 | |a staphylokinase | |
| 650 | 4 | |a streptokinase | |
| 650 | 4 | |a tenecteplase | |
| 650 | 4 | |a thrombolysis | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 700 | 1 | |a Martynov, M Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Yasamanova, A N |e verfasserin |4 aut | |
| 700 | 1 | |a Nikonov, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Markin, S S |e verfasserin |4 aut | |
| 700 | 1 | |a Semenov, A M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova |d 1997 |g 118(2018), 12. Vyp. 2 vom: 30., Seite 4-14 |w (DE-627)NLM074605267 |x 1997-7298 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2018 |g number:12. Vyp. 2 |g day:30 |g pages:4-14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17116/jnevro20181181224 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2018 |e 12. Vyp. 2 |b 30 |h 4-14 | ||